Subscribe to RSS
Download PDF
DOI: 10.4103/ijmpo.ijmpo_95_19
Oral Mucositis with Abiraterone Acetate: A Therapeutic Dilemma
Authors
Financial support and sponsorship Nil.
Abstract
Mucositis is a common complication of cancer treatment. Mucositis has varied etiology. Here, we describe a case of 71-year-old male with metastatic castrate-resistant carcinoma prostate who developed mucositis with the use of targeted therapy, and this particular scenario led to the therapeutic dilemma.
Publication History
Received: 10 April 2019
Accepted: 20 October 2019
Article published online:
17 May 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017; 377: 352-60
- 2 Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152-60
- 3 Scott LJ. Abiraterone acetate: A review in metastatic castration-resistant prostrate cancer. Drugs 2017; 77: 1565-76
- 4 Ramudo-Cela L, Balea-Filgueiras J, Vizoso-Hermida JR, Martín-Herranz I. Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience. J Oncol Pharm Pract 2017; 23: 615-9
- 5 Al-Ansari S, Zecha JA, Barasch A, de Lange J, Rozema FR, Raber-Durlacher JE. Oral mucositis induced by anticancer therapies. Curr Oral Health Rep 2015; 2: 202-11
- 6 Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B. et al. Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 2018; 36: 1389-95